Glioz 250mg Capsule contains the active ingredient temozolomide. It belongs to the class of medications known as Antitumor agents. It is prescribed to treat brain cancer, such as glioblastoma multiforme in adults and malignant glioma, including glioblastoma multiforme or anaplastic astrocytoma in patients older than three years. Glioblastoma and anaplastic astrocytoma are the most common and aggressive brain cancers with low chances of survival. Anaplastic astrocytoma is treated with Glioz 250mg Capsule or radiotherapy after biopsy, whereas Glioblastoma multiforme is treated with a combination of radiotherapy and Glioz 250mg Capsule, and it is continued as maintenance therapy.
